Soticlestat Revived: Perceptive Advisors Bets FDA Rejected Trial Design, Not Drug Itself

Soticlestat epilepsy drug revival: Perceptive Advisors has launched a new private company to develop soticlestat after Takeda abandoned the program following a narrow Phase 3 miss, giving rare hope to Dravet syndrome patients for whom 90% of currently approved treatments fail to provide adequate seizure control.